The impact of teriparatide adherence and persistence on fracture outcomes (Q43607111)

25 November 2017

The impact of teriparatide adherence and persistence on fracture outcomes (English)

1 reference

25 November 2017

1 reference

S Yu

1

1 reference

25 November 2017

R T Burge

2

1 reference

25 November 2017

S A Foster

3

1 reference

25 November 2017

S Gelwicks

4

1 reference

25 November 2017

E S Meadows

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

8 December 2011

1 reference

Osteoporosis International

25 November 2017

1 reference

25 November 2017

23

1 reference

25 November 2017

3

1 reference

25 November 2017

1103-1113

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-011-1843-3

25 November 2017

0 references

cites work

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Non-compliance: the Achilles' heel of anti-fracture efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Loss of treatment benefit due to low compliance with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Fracture outcomes related to persistence and compliance with oral bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Anti-epileptic medication and bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Design of the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

A meta-analysis of osteoporotic fracture risk with medication nonadherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1843-3

Characteristics of patients initiating teriparatide for the treatment of osteoporosis

21 January 2018

1 reference

12 December 2020

Compliance with osteoporosis drug therapy and risk of fracture

1 reference

12 December 2020

The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis

1 reference

12 December 2020

Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis

1 reference

12 December 2020

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

A review of the effect of anticonvulsant medications on bone mineral density and fracture risk

1 reference

12 December 2020

10.1007/S00198-011-1843-3

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

0 references

1 reference